Table 2.
Pharmacological treatment at baseline.
| General Characteristics | Total |
|---|---|
| ACE-I (%) | 30 |
| ARBs (%) | 0 |
| BBs (%) | 60 |
| Diuretics (%) | 100 |
| CCBs (%) | 10 |
| Antiplatelets (%) | 50 |
| Anticoagulants (%) | 50 |
| Anti-arrhythmics (%) | 30 |
| Vaso-dilators (%) | 0 |
| Digoxin (%) | 0 |
| MRAs (%) | 40 |
| ARNI (%) | 50 |
| SGLUT-2 (%) | 20 |
| Tafamidis (%) | 30 |